ライフサイエンスコーパス: therapeutic drug

1 RA is also a therapeutic drug.

2 pathway and a potentially clinically useful therapeutic drug.

3 alyses for the characterization of a protein therapeutic drug.

4 There is no licensed vaccine or therapeutic drug.

5 tually for designing new molecules toward AD therapeutic drugs.

6 ab-paclitaxel and other albumin-based cancer therapeutic drugs.

7 represent viable targets for development of therapeutic drugs.

8 ection, but also reduced penetration of many therapeutic drugs.

9 -production, without loading of any specific therapeutic drugs.

10 of mechanosensitive channels of pathogens by therapeutic drugs.

11 was used for the detection of two carbamate therapeutic drugs.

12 rgeted during the search for prophylactic or therapeutic drugs.

13 processes, making them important targets for therapeutic drugs.

14 for development of safe and effective cancer therapeutic drugs.

15 nals and are targets for a large fraction of therapeutic drugs.

16 an enzyme involved in the metabolism of many therapeutic drugs.

17 nesterase (AChE) is a significant target for therapeutic drugs.

18 s has a significant impact on the actions of therapeutic drugs.

19 serve as a basis for the development of new therapeutic drugs.

20 oviding a new framework for developing novel therapeutic drugs.

21 determinants with other SCI insecticides and therapeutic drugs.

22 receptors and are the most common target of therapeutic drugs.

23 onitor improved glycosylation in response to therapeutic drugs.

24 nd measure single cell responses, such as to therapeutic drugs.

25 in the clearance and detoxification of many therapeutic drugs.

26 gy of disease, and the responses of cells to therapeutic drugs.

27 t in neural cells and a potential target for therapeutic drugs.

28 thus reduce brain accumulation of CNS-acting therapeutic drugs.

29 innovative approaches to the development of therapeutic drugs.

30 TBI as well as a useful screening method for therapeutic drugs.

31 i and are the molecular targets for numerous therapeutic drugs.

32 linical applications of immunophilin-related therapeutic drugs.

33 tion, making them an attractive platform for therapeutic drugs.

34 vels and is the site of action of abused and therapeutic drugs.

35 osine phosphatases that can be targeted with therapeutic drugs.

36 killing and were cross-resistant to multiple therapeutic drugs.

37 sium channels are the site of action of many therapeutic drugs.

38 could be developed into effective anti-HIV-1 therapeutic drugs.

39 akes it a plausible target for this class of therapeutic drugs.

40 lity of SSAT are being explored as potential therapeutic drugs.

41 Derivatives have been developed as possible therapeutic drugs.

42 , genetic disorders, and exposure to certain therapeutic drugs.

43 is, might benefit differently from different therapeutic drugs.

44 opportunities for developing mechanism-based therapeutic drugs.

45 ential to speed up the screening process for therapeutic drugs.

46 d as targeting agents for imaging probes and therapeutic drugs.

47 and after exposure to neurotoxins including therapeutic drugs.

48 responsible for the poor penetration of many therapeutic drugs.

49 el blockers are among the most commonly used therapeutic drugs.

50 to understand tumorigenesis and develop new therapeutic drugs.

51 ation and therefore impact their efficacy as therapeutic drugs.

52 targets to modulation by potent and specific therapeutic drugs.

53 chemical toxins and carcinogens, and >80% of therapeutic drugs.

54 portant targets for the development of novel therapeutic drugs.

55 lism, efficacy, and side effects of numerous therapeutic drugs.

56 east in part, attributable to the effects of therapeutic drugs.

57 some(R) an efficient carrier for delivery of therapeutic drugs across the skin barrier.

58 atural compound could be used as a potential therapeutic drug against KSHV malignancies involving vGP

59 delineate human TREX complex as a target for therapeutic drugs against breast cancer.

60 mportant target for the development of novel therapeutic drugs against human diseases.

61 /LR is a potential target for developing new therapeutic drugs against neurodegenerative disorders su

62 equire new practices including more frequent therapeutic drug and clinical monitoring, and increased

63 ein inhibitors, molecular detection systems, therapeutic drugs and antibody replacement among others.

64 ease measurement, and the development of new therapeutic drugs and approaches are needed to improve o

65 tate further development of Fabs as possible therapeutic drugs and biochemical tools to explore RNA b

66 s may provide novel opportunities to develop therapeutic drugs and chemical tools.

67 stigated and considered for oral delivery of therapeutic drugs and diagnostic materials.

68 xicities but also may reveal new targets for therapeutic drugs and diagnostic tools.

69 s of the gut microbiome on the metabolism of therapeutic drugs and diet-derived bioactive compounds.

70 ic cytochromes P450 (CYP450s) in response to therapeutic drugs and environmental contaminants, leadin

71 Therapeutic drugs and environmental pollutants may exhib

72 n of numerous hepatic genes upon exposure to therapeutic drugs and environmental pollutants.

73 well as by various other xenobiotics such as therapeutic drugs and environmental pollutants.

74 t enzyme that metabolizes both commonly used therapeutic drugs and important endogenous compounds.

75 chloride co-transporters that are targets of therapeutic drugs and mutated in several human diseases.

76 ge depot for small organic molecules such as therapeutic drugs and pollutants such as DDT, as well as

77 ctivity could be altered by exposure to some therapeutic drugs and potentially other xenobiotics.

78 n tumor bulk, leading to reduced efficacy of therapeutic drugs and radiotherapy.

79 nto improved diagnostics and new targets for therapeutic drugs and vaccines.

80 lasm of liver cells before its activation by therapeutic drugs and xenobiotics such as phenobarbital

81 nd PXR activate hepatic genes in response to therapeutic drugs and xenobiotics, leading to the induct

82 has been demonstrated that multiple types of therapeutic drugs and/or diagnostic agents (e.g., contra

83 derlying neurobiology of ASD and identifying therapeutic drugs and/or drug targets.

84 he GPP subpocket, as compared to the current therapeutic drugs, and rigidify the (364)KRRK(367) tail

85 Monitoring the concentration of a therapeutic drug antibody, infliximab (IFX), is recommen

86 Consequently, therapeutic drugs are designed to target GPCRs at the pl

87 rging resistance to current medications, new therapeutic drugs are needed.

88 major therapeutic importance, and potential therapeutic drugs are screened against SIRT1 deacetylase

89 d chain to revolutionize the way many labile therapeutic drugs are stored and utilized throughout the

90 afosfamide and fludarabine showed that these therapeutic drugs are synergistic in B-CLL whole blood a

91 They show that the therapeutic drug arsenic trioxide (AS(2)O(3)) targets BC

92 Monitoring of trace-levels of chemicals in therapeutic drugs, as well as in food safety and environ

93 They also prevent the entry of therapeutic drugs at the BBB, thereby limiting their eff

94 of other analytes including theophylline, a therapeutic drug, at a concentration as low as 1.0 x 10(

95 dies (mAbs) are the fastest growing class of therapeutic drugs, because of their high specificities t

96 al advances in stroke research, with several therapeutic drugs being able to enhance clinical outcome

97 fully demonstrated by the N-oxidation of two therapeutic drugs, benzydamine (nonsteroidal anti-inflam

98 anning electron microscopy revealed that the therapeutic drug candidate beta-cyclodextrin induces the

99 luated further as a potential preventive and therapeutic drug candidate for AD.

100 rylation and suggest that LY5 is a promising therapeutic drug candidate for medulloblastoma by inhibi

101 K using the approved drug denosumab may be a therapeutic drug candidate for primary lung cancer.

102 drug discovery programmes, as many potential therapeutic drug candidates have poor BBB permeation.

103 toxicity induced by the frontline anticancer therapeutic drug cisplatin, which has been associated wi

104 The therapeutic drug, cisplatin decreases MdmX protein expre

105 If an inhibitor leading to a therapeutic drug common to all serotypes is to be develo

106 d toward effective point-of-care devices for therapeutic drug concentration monitoring.

107 e exact tumor site as well as an appropriate therapeutic drug concentration with a controlled release

108 By contrast, sustained therapeutic drug concentrations in aqueous humor can be

109 hat the delivery of high doses could achieve therapeutic drug concentrations in the brain and cerebro

110 rial immune functions were studied by use of therapeutic drug concentrations in whole-blood culture.

111 ne is able to reverse GC resistance, even at therapeutic drug concentrations.

112 molecules per second enter each hair cell at therapeutic drug concentrations.

113 Resistance of leishmanial parasites to therapeutic drugs continues to escalate in developing co

114 While the application of EVs for therapeutic drug delivery is still in its infancy, issue

115 Harnessing exosomes as therapeutic drug delivery vehicles requires a better und

116 neural stimulation, neural regeneration, and therapeutic drug delivery.

117 an effort to identify additional targets for therapeutic drug design in NF1, we used an unbiased prot

118 ted astrocytomas that could be exploited for therapeutic drug design, we did an objective proteomic a

119 signaling may also have implications for the therapeutic drug design.

120 these PKC isoforms are important targets for therapeutic drug design.

121 is now changing, and strategies for rational therapeutic drug development are emerging that have the

122 aspase-6 has been identified as a target for therapeutic drug development for the treatment of this d

123 atory site that also represents a target for therapeutic drug development.

124 stable foldon and suggest new strategies for therapeutic drug development.

125 eful discovery tool for novel biomarkers and therapeutic drug development.

126 n and contribute to both delays and costs of therapeutic drug development.

127 The role of molecular imaging in the therapeutic drug discovery process will also be reviewed

128 Significant investments in therapeutic drug discovery programs over the past two de

129 de bladder cancer to serve as a platform for therapeutic drug discovery.

130 ess of protein kinase inhibitors as approved therapeutics, drug discovery has focused on a small subs

131 This strategy allows for a reduction in the therapeutic drug dose, which may reduce harmful side eff

132 he respiratory drive at 0.1% of the systemic therapeutic drug dose.

133 ry pain may be an important consideration in therapeutic drug dosing, potential adverse effects and/o

134 tivity or sensitize p53 to activation by the therapeutic drugs doxorubicin and actinomycin D.

135 of schizophrenia and to monitor potentially therapeutic drug effects for both treatment and preventi

136 Therapeutic drug efficacy and tolerability of memantine

137 are important human enzymes that metabolize therapeutic drugs, environmental chemicals, and physiolo

138 ample, they participate in the metabolism of therapeutic drugs, fatty acids, eicosonoids, sterols, st

139 ine (CQ) has been used as first line malaria therapeutic drug for decades.

140 ion; therefore, it could possibly be a novel therapeutic drug for fibrosis.

141 piprazole represents a potentially promising therapeutic drug for Machado-Joseph disease and possibly

142 f stroke and has passed clinical trials as a therapeutic drug for stroke in China.

143 o study the metabolism of DOPA, a well-known therapeutic drug for treating Parkinson's disease.

144 form of arsenic trioxide (ATO) is used as a therapeutic drug for treatment of acute promyelocytic le

145 al cancer effects of metformin, a first-line therapeutic drug for type 2 diabetes mellitus, and nelfi

146 Cisplatin is one of the most commonly used therapeutic drugs for cancer therapy, yet prolonged cisp

147 2) over a 12-week period in the Genome-Based Therapeutic Drugs for Depression (GENDEP) project, a par

148 he hypothesis was tested in the Genome-Based Therapeutic Drugs for Depression (GENDEP) study, a multi

149 de pharmacogenetic studies (the Genome-Based Therapeutic Drugs for Depression [GENDEP] project, the M

150 3) a pharmacogenetic study (the Genome-Based Therapeutic Drugs for Depression [GENDEP] study; N=88).

151 elopment will accelerate the delivery of new therapeutic drugs for front-line therapy for those child

152 hat are currently underway to find effective therapeutic drugs for KRAS mutant lung cancer.

153 ntially lethal but also have applications as therapeutic drugs for neurodegenerative diseases such as

154 the impact of selected ferrociphenols as new therapeutic drugs for such cancers.

155 onal antibodies are most rapidly emerging as therapeutic drugs for the treatment of cancer and of var

156 cluding amphetamines and cocaine, as well as therapeutic drugs for the treatment of depression, addic

157 ncover a potential new target for developing therapeutic drugs for the treatment of insulin resistanc

158 so suggest approaches for the development of therapeutic drugs for the treatment of striatal-based br

159 ses could greatly help in the development of therapeutic drugs for the treatment of these pathologies

160 to lead to the development of a new class of therapeutic drugs for treating LCA.

161 rgeted small molecules have shown promise as therapeutic drugs for treating RA.

162 at selective TRPV1 antagonists are potential therapeutic drugs for treating retinoid-induced sensory

163 as dantrolene may be considered as potential therapeutic drugs for treatment of SCA3 patients.

164 The therapeutic drugs gabapentin and pregabalin (PGB), which

165 l resistance to currently approved influenza therapeutic drugs has developed.

166 ditions, the encapsulated imaging agents and therapeutic drugs have been successfully delivered to ta

167 metabolic response to the targeted molecular therapeutic drug imatinib mesylate.

168 inflammatory properties has been tested as a therapeutic drug in clinical trials of China.

169 investigate gene regulation in response to a therapeutic drug in humans.

170 cancer cell resistance, low accumulation of therapeutic drug in the lungs, and severe adverse treatm

171 g and quantitating controlled substances and therapeutic drugs in biofluids typically require laborio

172 can serve as a model for the development of therapeutic drugs in combating Parkinson's disease.

173 red in an attempt to improve the analysis of therapeutic drugs in dried blood spots (DBS).

174 f nucleosides, nucleobases, and a variety of therapeutic drugs in eukaryotes from protozoa to mammals

175 emely valuable in monitoring the response to therapeutic drugs in many cancers.

176 a promising strategy for the design of novel therapeutic drugs in Parkinson's disease.

177 nt creates a physiological barrier for using therapeutic drugs in the stomach.

178 ated potassium (Kv) channels are targets for therapeutic drugs in the treatment of pathologic conditi

179 es as targeting motifs, and the inclusion of therapeutic drugs in their composition, is certain to ma

180 s below 10%, have been obtained for selected therapeutic drugs in whole blood throughout their indivi

181 f action for most neurotransmitters and many therapeutic drugs, including typical and atypical antips

182 te targeting ligands, imaging agents, and/or therapeutic drugs into particles as an integral part of

183 y dramatically increases penetration of many therapeutic drugs into the CNS.

184 ines to probe receptor biology or to develop therapeutic drugs is limited by their lack of selectivit

185 results provide proof of concept for BKIs as therapeutic drug leads in an animal model for human cryp

186 he use of de novo sirolimus requires careful therapeutic drug level monitoring, especially the first

187 been used in the clinic to provide sustained therapeutic drug levels at a target site, and thereby re

188 lectivity specifically to the heart, wherein therapeutic drug levels can be maintained over time, is

189 CEP-1347-treated mice readily achieve therapeutic drug levels in peripheral blood.

190 n effective approach to achieving sustained, therapeutic drug levels in the eye.

191 ough a single infant was reported to develop therapeutic drug levels.

192 (8%), despite rapid viremia suppression and therapeutic drug levels; for 10 months, this virus remai

193 acks from chronic viral infection, uptake of therapeutic drugs, life behavior (alcoholic), and enviro

194 adults, the new born is "plastic," and even therapeutic drugs may produce "silent" programming defec

195 a gravis) raises the possibility that future therapeutic drugs might target specific AChE variant(s)

196 Therapeutic drug monitoring (TDM) aid therapeutic decisi

197 greatly facilitates using the DBS method for therapeutic drug monitoring (TDM) for improving the effi

198 The importance of therapeutic drug monitoring (TDM) in this population is

199 h a narrow therapeutic dosage range to which therapeutic drug monitoring (TDM) is applied.

200 ssue of Blood, Tong et al have reported that therapeutic drug monitoring (TDM) of asparaginase (ASP)

201 Therapeutic drug monitoring (TDM) provides valuable guid

202 are market analytical platforms that perform therapeutic drug monitoring (TDM) without relying on mAb

203 Therapeutic drug monitoring (TDM), which involves measur

204 man spectroscopy as point-of-care method for therapeutic drug monitoring (TDM).

205 pecificity, making it an ideal candidate for therapeutic drug monitoring (TDM).

206 used in clinical chemistry laboratories for therapeutic drug monitoring (TDM).

207 anagement strategy that incorporates routine therapeutic drug monitoring and dose adjustment over cur

208 ce pharmacokinetic variability by the use of therapeutic drug monitoring and include measurement of t

209 gnized, with multiple applications in, e.g., therapeutic drug monitoring and toxicology.

210 virologically suppressed, in settings where therapeutic drug monitoring and/or close viral load moni

211 h the use of dosing software supplemented by therapeutic drug monitoring data should be embedded into

212 Therapeutic drug monitoring did not reveal any clinicall

213 Therapeutic drug monitoring has been added to our ALL-11

214 macogenetics has the potential to complement therapeutic drug monitoring in achieving target blood co

215 lopathy and those evaluating the role of MMF therapeutic drug monitoring in cardiac transplant recipi

216 e aimed to determine whether dosing based on therapeutic drug monitoring increases rate of remission

217 te exposure of fluconazole improves outcome, therapeutic drug monitoring is currently not recommended

218 Therapeutic drug monitoring is seen as a valuable tool t

219 Therapeutic drug monitoring may be advantageous when the

220 Therapeutic drug monitoring of fluconazole can be a valu

221 omes can be achieved without CNI drugs, when therapeutic drug monitoring of sirolimus is employed.

222 Therefore, it is highly recommended for therapeutic drug monitoring to control the drug level.

223 n the denaturating solution used in standard therapeutic drug monitoring to detach the drug from the

224 Intravenous busulfan combined with therapeutic drug monitoring to guide dosing improves out

225 y), and to personalize and optimize therapy (therapeutic drug monitoring).

226 l, (7) document antibiotic plan, (8) perform therapeutic drug monitoring, and (9) discontinue antibio

227 should incorporate rapid fungal diagnostics, therapeutic drug monitoring, and clinical intervention t

228 ation for bioanalytical applications such as therapeutic drug monitoring, doping in sports, and pharm

229 care, personal diagnosis or for personalized therapeutic drug monitoring.

230 ping in sports, in vivo tissue sampling, and therapeutic drug monitoring.

231 rgeted drug delivery, molecular imaging, and therapeutic drug monitoring.

232 ed, thus offering a tool for pharmacodynamic therapeutic drug monitoring.

233 tein drebrin, was blocked by the Alzheimer's therapeutic drug Namenda.

234 a biocompatible platform for the delivery of therapeutic drugs or diagnostics, (b) conjugation of pro

235 Therefore, the need of more effective therapeutic drugs or strategies for these two types of c

236 There are currently no approved therapeutic drugs or vaccines for the disease.

237 ination of the primary sequence of a protein therapeutic drug product.

238 e as 3D tissue engineering scaffolds and for therapeutic drug-release applications.

239 l as designed control for biodegradation and therapeutic drug-release capacity-is the main aim of man

240 nsmitter transporters, targets of abused and therapeutic drugs, require Na(+) and Cl(-) for function.

241 ed to be one of the greatest achievements in therapeutic drug research having transformed HIV infecti

242 toxic changes reflecting the transition from therapeutic drug responses to toxic reactions at the cel

243 we reveal how beta-cyclodextrin, a potential therapeutic drug, reverts these changes.

244 ents a promising cellular tool to facilitate therapeutic drug screening for severe neurodevelopmental

245 a powerful in vivo tool for high-throughput therapeutic drug screening for the improvement of muscle

246 lpha-synuclein-related pathologies and allow therapeutic drug screening.

247 targeting PTP1B and its analogs could be the therapeutic drug-seeds.

248 tion of apoptosis, cell differentiation, and therapeutic drug sensitivity.

249 at prehospital treatment is beneficial, that therapeutic drugs should be used in rapid sequence accor

250 rotocells can be loaded with combinations of therapeutic (drugs, small interfering RNA and toxins) an

251 as drug metabolism (approximately 85-90% of therapeutic drugs), steroid biosynthesis, and bioactive

252 estimate the potential savings of generic or therapeutic drug substitutions and price negotiation.

253 Savings from generic or therapeutic drug substitutions were estimated for brand

254 and targeted by approximately 60% of current therapeutic drugs such as beta-blockers, antipsychotics

255 n of the TGF-b pathway resensitizes cells to therapeutic drugs, suggesting a new combinatorial cancer

256 receptor, which may therefore offer a novel therapeutic drug target in the prevention and the treatm

257 suggesting this molecule as a prognostic and therapeutic drug target that could help improve the trea

258 arget for serotonin in the human brain and a therapeutic drug target.

259 rable interest in view of its potential as a therapeutic drug target.

260 ion and psychosis, providing a potential new therapeutic drug target.

261 n or the development of diagnostic tools and therapeutic drugs targeting disease-causing RNAs.

262 ajor significance for the design of novel AD therapeutic drugs targeting this APP domain.

263 The investigation of V-ATPases as potential therapeutic drug targets and hence of their specific inh

264 on, establishing these proteins as potential therapeutic drug targets for trypanosomiasis.

265 ysiology and represent an important class of therapeutic drug targets.

266 e muscarinic receptor subtype family hold as therapeutic drug targets.

267 n to reveal molecular pathways and potential therapeutic drug targets.

268 luding SSAT, are being explored as potential therapeutic drug targets.

269 nsferases involved is key to identifying new therapeutic drug targets.

270 nsferases involved is key to identifying new therapeutic drug targets.

271 ynucleinopathy pathogenesis and as potential therapeutic drug targets.SIGNIFICANCE STATEMENT Neurodeg

272 Therapeutic drugs that block DNA repair, including poly(

273 from two clinical trials of biomarker-guided therapeutic drugs that boosted immunity showed promising

274 1 is an essential step in the development of therapeutic drugs that could be useful in the treatment

275 PCRs are regulated, as a basis for designing therapeutic drugs that evade this regulation.

276 a promising molecular target for developing therapeutic drugs that exert their anticancer activities

277 s limited studies examine fibrates and other therapeutic drugs that induce cholestasis, a common find

278 This information is necessary for developing therapeutic drugs that inhibit and control amyloid forma

279 Histone deacetylase inhibitors (HDACIs) are therapeutic drugs that inhibit deacetylase activity, the

280 hat some cell types may be more sensitive to therapeutic drugs that inhibit the Mdm-p53 interaction.

281 sly unknown biological targets for designing therapeutic drugs that may prevent the development of ti

282 ritical FDC-SMs may lead to the discovery of therapeutic drugs that suppress the survival and growth

283 which may lead to the identification of new therapeutic drugs that target novel sites on nAChRs.

284 ass spectrometry for the analysis of protein therapeutic drugs, thus providing a foundation for futur

285 lts indicate that AICAR can be utilized as a therapeutic drug to inhibit cancer, and AMPK can be a po

286 development of ISIS-APO(a)Rx as a potential therapeutic drug to reduce the risk of cardiovascular di

287 el and identifies regorafenib as a potential therapeutic drug to treat this cancer type that mimic th

288 ch-1-regulating flavonoid compounds as novel therapeutic drugs to regulate radiosensitivity in NSCLC

289 The delivery of therapeutic drugs to solid tumours may be impaired by st

290 aled here may be targeted for development of therapeutic drugs to treat and prevent adenovirus-associ

291 number of small-molecule ligands, including therapeutic drugs under development and in clinical use,

292 s and animal models of narcolepsy, including therapeutic drug use and species differences.

293 otal antimicrobial use, but at the same time therapeutic drug use has increased and resistance in key

294 two reversible inhibitors, which are used as therapeutic drugs, was detectable by SPR without the nee

295 may be of use for modulating the effects of therapeutic drugs, which are potent agonists for this re

296 substantially increased, and preventive and therapeutic drugs will probably become available within

297 Fingolimod (FTY720) is an FDA-approved therapeutic drug with efficacy demonstrated in experimen

298 tegrin treatment efficacy and to develop new therapeutic drugs with favorable tumor targeting and in

299 Therapeutic drugs with ototoxic side effects cause signi

300 ells are sensitive to death from exposure to therapeutic drugs with ototoxic side effects, including